Novartis AG (NVS)
NYSE: NVS · Real-Time Price · USD
129.73
+1.31 (1.02%)
At close: Sep 5, 2025, 4:00 PM
129.73
0.00 (0.00%)
After-hours: Sep 5, 2025, 6:30 PM EDT
Novartis AG Employees
Novartis AG had 75,883 employees as of December 31, 2024. The number of employees decreased by 174 or -0.23% compared to the previous year.
Employees
75,883
Change (1Y)
-174
Growth (1Y)
-0.23%
Revenue / Employee
$727,251
Profits / Employee
$179,935
Market Cap
252.55B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 75,883 | -174 | -0.23% |
Dec 31, 2023 | 76,057 | -25,646 | -25.22% |
Dec 31, 2022 | 101,703 | -2,620 | -2.51% |
Dec 31, 2021 | 104,323 | -1,471 | -1.39% |
Dec 31, 2020 | 105,794 | 1,880 | 1.81% |
Dec 31, 2019 | 103,914 | -21,247 | -16.98% |
Dec 31, 2018 | 125,161 | 3,564 | 2.93% |
Dec 31, 2017 | 121,597 | 3,204 | 2.71% |
Dec 31, 2016 | 118,393 | -307 | -0.26% |
Dec 31, 2015 | 118,700 | -14,713 | -11.03% |
Dec 31, 2014 | 133,413 | -2,283 | -1.68% |
Dec 31, 2013 | 135,696 | 7,972 | 6.24% |
Dec 31, 2012 | 127,724 | 4,038 | 3.26% |
Dec 31, 2011 | 123,686 | 4,268 | 3.57% |
Dec 31, 2010 | 119,418 | 19,584 | 19.62% |
Dec 31, 2009 | 99,834 | 3,117 | 3.22% |
Dec 31, 2008 | 96,717 | -1,483 | -1.51% |
Dec 31, 2007 | 98,200 | -2,535 | -2.52% |
Dec 31, 2006 | 100,735 | 9,735 | 10.70% |
Dec 31, 2005 | 91,000 | 9,600 | 11.79% |
Dec 31, 2004 | 81,400 | 2,859 | 3.64% |
Dec 31, 2003 | 78,541 | 5,664 | 7.77% |
Dec 31, 2002 | 72,877 | 2,557 | 3.64% |
Dec 31, 2001 | 70,320 | 1,252 | 1.81% |
Dec 31, 2000 | 69,068 | -13,391 | -16.24% |
Dec 31, 1999 | 82,459 | -3,376 | -3.93% |
Dec 31, 1998 | 85,835 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Merck & Co. | 75,000 |
AbbVie | 55,000 |
NVS News
- 2 days ago - Global drugmakers rush to boost US presence as tariff threat looms - Reuters
- 2 days ago - Novartis signs up to $5.2 billion licensing deal with Argo Biopharmaceutical for heart drugs - Reuters
- 2 days ago - Argo Biopharma Announces Multi-Asset License and Option Agreements with Novartis for Novel Molecules for Cardiovascular Diseases - PRNewsWire
- 2 days ago - Novartis: Pipeline Progress And Buyback Drive Upside - Seeking Alpha
- 3 days ago - Arrowhead and Novartis agree up to $2 billion deal for license to neuromuscular therapy - Reuters
- 6 days ago - Novartis Leqvio® shows statistically significant and clinically meaningful early LDL-C goal achievement with less muscle pain - GlobeNewsWire
- 10 days ago - BioArctic and Novartis sign an option, collaboration and license agreement using BrainTransporter™ for an upfront payment of USD 30 million plus additional potential milestones and royalties - PRNewsWire
- 18 days ago - New Novartis ESC data highlights strength of cardiovascular portfolio - GlobeNewsWire